Please assess the completion status of the following clinical trial:

Trial Title: Melatonin Levels in Smith Magenis Syndrome (SMS)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Control participants:~  * 30 individuals: ages 55-85,~ * healthy without significant active medical problems.~* SMS patients:~  * 20 individuals: ages 3-50,~ * with a clinical diagnosis of Smith-Magenis Syndrome by a qualified Medical Geneticist, confirmed by cytogenetic analysis documenting deletion of chromosome band 17p11.2.~Exclusion Criteria:~* Control participants:~  * A current Axis I psychiatric or substance abuse disorder according to the DSM-IV Manual, abnormal heart, liver or kidney function, diagnoses of neurodegenerative or cerebrovascular disease (Alzheimer's disease, Parkinson's disease, stroke, etc.),~ * cognitive impairment (Mini-Mental State Score \< 23) but without a formal diagnosis of dementia,~ * active symptoms of depression (Geriatric Depression Scale: 30 pt. version \> 10),~ * current diagnosis of cataracts,~ * macular degeneration or retinopathy based on eye exam by an optometrist or ophthalmologist within the past year.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- 2 (Type: ACTIVE_COMPARATOR): Subjects will sit in front of a fluorescent bright light box while completing plasma samples to test for melatonin suppression in blood. This will be completed by both the SMS patient group and the control group of elderly individuals.
- 1 (Type: EXPERIMENTAL): Subjects will take up to 3 mg of melatonin daily and will complete frequent (every 2-4 weeks) of saliva and/or plasma sampling to test for a change in the timing of the body clock in response to the melatonin.

Based on this trial design, predict the completion outcome and termination type (if applicable).